Author/Authors :
Yousefnia, Hassan Radiopharmaceutical Research and Development Lab - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Jalilian, Amir Reza Radiopharmaceutical Research and Development Lab - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Bahrami-Samani, Ali Radiopharmaceutical Research and Development Lab - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Mazidi, Mohammad Radiopharmaceutical Research and Development Lab - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Ghannadi Maragheh, Mohammad Radiopharmaceutical Research and Development Lab - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Abbasi-Davani, Fereydoun Radiation Application Group - Faculty of Nuclear Engineering - Shahid Beheshti University, Tehran
Abstract :
Objective(s): In this work a new possible agent for radiosynovectomy has been targeted for articular pain palliation. Materials and Methods: Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 4 × 1013 n.cm-2.s-1. The product was converted into chloride form which was further used for labeling of 177Lu-phytate complex and checked using ITLC (MeOH: H2O: acetic acid, 4: 4: 2, as mobile phase). The complex stability and viscosity were checked in the final solution up to seven days. The prepared complex solution (100 μCi/100 μl) was injected intra-articularly to male rat knee joint. Leakage of radioactivity from injection site and its distribution in organs were investigated up to seven days. Results: The complex was successfully prepared with high radiochemical purity (>99.9 %). Approximately, the whole injected dose has remained in injection site seven days after injection. Conclusion: The complex was proved to be a feasible agent for cavital radiotherapy in oncology and r heumatology.
Keywords :
Biodistribution , Lutetium-177 , Phytate , Radiosynovectomy
